Crisugabalin vs Mirogabalin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Diabetic Peripheral Neuropathic Pain
Shared mechanism: α2δ-1 subunit of voltage-gated calcium channels · full Diabetic Peripheral Neuropathic Pain pipeline
Crisugabalin
Marketed by Haisco Pharmaceutical Group
NCT04647773 · Phase 2/3 · status unknown
Adaptive Phase 2/3, multicentre, double-blind trial controlled by placebo and pregabalin (725 patients randomised). At week 13 both recommended doses (40 and 80 mg/d) reduced the average daily pain score more than placebo (-2.24 and -2.16 vs -1.23; both P < .001).
Next expected readout: August 2028 · NCT07859111 (registry estimate)
Reported efficacy
Change from baseline in Average Daily Pain Score (ADPS) at Week 13: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001) (met)
Result source: NCT04647773
Mirogabalin
Marketed by Daiichi Sankyo and partners
NCT02318706 · Phase 3 · completed
Participants were randomized to three mirogabalin doses or placebo and treatment was double-blinded, with 834 randomized participants. The primary clinical pain endpoint had mixed results: the 30-mg dose was significantly better than placebo, while the 15-mg and 20-mg comparisons were not statistically significant, so the findings provide meaningful but mixed evidence.
Next expected readout: March 2027 · NCT07451431 (registry estimate)
Reported efficacy
Average Daily Pain Score (ADPS) (Baseline to Week 14): Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301 (met)
Result source: NCT04094662
Results for Diabetic Peripheral Neuropathic Pain
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Crisugabalin | Mirogabalin |
|---|---|---|
| Average daily pain, change | —Trial running · NCT07859111 | -1.8 vs -1.5−0.2 vs placeboNCT0150441220 other results
|
| 30% pain reduction | —Trial running · NCT07859111 | —Not posted · NCT04094662 |
| 50% pain reduction | —Trial running · NCT07859111 | —Not posted · NCT04094662 |
| Sleep interference, change | —Trial running · NCT07859111 | —Not posted · NCT04094662 |
Average daily pain, change
- Crisugabalin
- —Trial running · NCT07859111
- Mirogabalin
- -1.8 vs -1.5−0.2 vs placeboNCT01504412
20 other results
- -1.7 vs -1.4 NCT01504412
- -1.5 vs -1.3 NCT01504412
- -1.6 vs -1.1 NCT01504412
- -1.4 vs -1.1 NCT01504412
- -1.1 vs -0.9 NCT01504412
- -0.6 vs -0.6 NCT01504412
- -1.9 vs -1.5 NCT01504412
- -1.8 vs -1.4 NCT01504412
- -1.7 vs -1.3 NCT01504412
- -1.6 vs -1.1 NCT01504412
- -1.5 vs -1.1 NCT01504412
- -1.2 vs -0.9 NCT01504412
- -0.9 vs -0.6 NCT01504412
- -1.8 vs -1.5 NCT01504412
- -1.8 vs -1.4 NCT01504412
- -1.6 vs -1.3 NCT01504412
- -1.5 vs -1.1 NCT01504412
- -1.3 vs -1.1 NCT01504412
- -1.2 vs -0.9 NCT01504412
- -0.7 vs -0.6 NCT01504412
30% pain reduction
- Crisugabalin
- —Trial running · NCT07859111
- Mirogabalin
- —Not posted · NCT04094662
50% pain reduction
- Crisugabalin
- —Trial running · NCT07859111
- Mirogabalin
- —Not posted · NCT04094662
Sleep interference, change
- Crisugabalin
- —Trial running · NCT07859111
- Mirogabalin
- —Not posted · NCT04094662
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Crisugabalin: 0 of 4 rows · Mirogabalin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Mirogabalin |
|---|---|
| Dropout rate | 14.5%30 mg (15 mg BID)a NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 show 12 more results10.7%20 mg (10 mg BID) NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 7.2%15 mg QD NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 13.3%Moderate Renal Impairment NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 20%Severe Renal Impairment NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 14.4%30 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 20.2%20 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 4.4%10 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 22.8%15 mg QD NCT01496365 · Phase 2 · registry result, not featured evidence 10.5%15 mg BID NCT01496365 · Phase 2 · registry result, not featured evidence 17.9%10 mg BID NCT01496365 · Phase 2 · registry result, not featured evidence 7%10 mg QD NCT01496365 · Phase 2 · registry result, not featured evidence 10.5%5mg QD NCT01496365 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 6%30 mg (15 mg BID)a NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 show 12 more results1.8%20 mg (10 mg BID) NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 2.4%15 mg QD NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 13.3%Moderate Renal Impairment NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 0%Severe Renal Impairment NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 11.1%30 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 7.4%20 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 1.1%10 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 8.8%15 mg QD NCT01496365 · Phase 2 · registry result, not featured evidence 7%15 mg BID NCT01496365 · Phase 2 · registry result, not featured evidence 10.7%10 mg BID NCT01496365 · Phase 2 · registry result, not featured evidence 3.5%10 mg QD NCT01496365 · Phase 2 · registry result, not featured evidence 5.3%5mg QD NCT01496365 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.7%30 mg (15 mg BID)a NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 show 12 more results4.8%20 mg (10 mg BID) NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 2.4%15 mg QD NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 3.3%Moderate Renal Impairment NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 0%Severe Renal Impairment NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 2.2%30 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 4.3%20 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 1.1%10 mg/Day NCT01504412 · Phase 2 · registry result, not featured evidence 3.8%15 mg QD NCT01496365 · Phase 2 · registry result, not featured evidence 0%15 mg BID NCT01496365 · Phase 2 · registry result, not featured evidence 1.8%10 mg BID NCT01496365 · Phase 2 · registry result, not featured evidence 5.4%10 mg QD NCT01496365 · Phase 2 · registry result, not featured evidence 3.6%5mg QD NCT01496365 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 30 mg (15 mg BID)a nasopharyngitis 16.4% (placebo 12.7%) somnolence 14.5% (placebo 3.9%) dizziness 10.9% (placebo 2.1%) NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 show 12 more results20 mg (10 mg BID) nasopharyngitis 14.5% (placebo 12.7%) somnolence 12.1% (placebo 3.9%) dizziness 8.5% (placebo 2.1%) NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 15 mg QD nasopharyngitis 13.4% (placebo 12.7%) somnolence 8.5% (placebo 3.9%) dizziness 4.9% (placebo 2.1%) NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 nasopharyngitis 20% somnolence 13.3% back pain 6.7% NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 nasopharyngitis 40% oedema peripheral 20% back pain 0% NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3 30 mg/Day somnolence 21.1% (placebo 5.7%) dizziness 16.7% (placebo 3.4%) oedema peripheral 7.8% (placebo 1.1%) NCT01504412 · Phase 2 · registry result, not featured evidence 20 mg/Day nasopharyngitis 14% (placebo 3.4%) somnolence 14% (placebo 5.7%) dizziness 10.8% (placebo 3.4%) NCT01504412 · Phase 2 · registry result, not featured evidence 10 mg/Day somnolence 8.9% (placebo 5.7%) nasopharyngitis 7.8% (placebo 3.4%) dizziness 5.6% (placebo 3.4%) NCT01504412 · Phase 2 · registry result, not featured evidence 15 mg QD dizziness 11.3% (placebo 1.9%) fatigue 7.5% (placebo 1.9%) somnolence 5.7% (placebo 0.9%) NCT01496365 · Phase 2 · registry result, not featured evidence 15 mg BID dizziness 15.8% (placebo 1.9%) somnolence 12.3% (placebo 0.9%) balance disorder 5.3% (placebo 0%) NCT01496365 · Phase 2 · registry result, not featured evidence 10 mg BID headache 8.9% (placebo 3.7%) somnolence 8.9% (placebo 0.9%) dizziness 7.1% (placebo 1.9%) NCT01496365 · Phase 2 · registry result, not featured evidence 10 mg QD dizziness 12.5% (placebo 1.9%) constipation 8.9% (placebo 1.9%) headache 7.1% (placebo 3.7%) NCT01496365 · Phase 2 · registry result, not featured evidence 5mg QD headache 10.9% (placebo 3.7%) diarrhoea 5.5% (placebo 2.8%) nausea 3.6% (placebo 1.9%) NCT01496365 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Mirogabalin
show 66 more results
show 28 more results
show 20 more results
show 2 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crisugabalin's landscape · Mirogabalin's landscape